On the other hand, if theres minimal improvement after a fair trial (e.g., 48 doses over 2 months), guidelines would suggest discontinuing PT-141fda.gov and exploring other options
Moreover, such factors as the size and composition of the test meal, in addition to abnormal glucose metabolism and excess body weight/fat of our test subjects, may have contributed to the null findings
Additionally, GLP-1s have shown potential in helping with addiction and substance dependencies
Takeaway: For HFpEF patients with obesity + T2D, GLP-1s and dual agonists are emerging not only as metabolic therapies but as cardiovascular disease-modifying agents
Visit us at Perfect B, Doral FL, serving Miami and South Florida patients seeking metabolic and weight loss peptide therapy